This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 1 for:    NCT00546988
Previous Study | Return to List | Next Study

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2007 by University of Wuerzburg.
Recruitment status was:  Recruiting
Information provided by:
University of Wuerzburg Identifier:
First received: October 17, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted
The study is evaluating whether risk-stratification by the means of a chromosomal aberration provides a tool to discriminate between standard and high risk. Risk-adapted therapy is based on allogeneic stem-cell transplantation for high-risk subjects instead of a second autograft in patients with deletion of chromosome 13 who have an HLA-identical stem cell donor available.

Condition Intervention Phase
Multiple Myeloma Biological: allogeneic stem cell transplant Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multizentrische Therapiestudie Des Multiplen Myeloms DSMM V Therapieoptimierungs-Studie Der Deutschen Studiengruppe Multiples Myelom für Patienten Bis 60 Jahre im Stadium II/III

Resource links provided by NLM:

Further study details as provided by University of Wuerzburg:

Primary Outcome Measures:
  • Response rate after high-dose therapy [ Time Frame: one year ]

Secondary Outcome Measures:
  • Response rate and treatment-related mortality after allogeneic transplantation [ Time Frame: one year ]

Estimated Enrollment: 600
Study Start Date: October 2001
Estimated Study Completion Date: January 2008
Arms Assigned Interventions
No Intervention: Standard risk IFN
Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
No Intervention: Standard risk PEGIFN
Maintenance treatment with pegylated interferon following autologous stem cell transplantation
Experimental: High risk allo
Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
Biological: allogeneic stem cell transplant
No Intervention: High risk auto
Second cycle of high-dose melphalan in subjects without an HLA-identical donor

Detailed Description:
The DSMM V protocol is to compare a consolidation treatment for standard-risk patients not displaying del(13) at initial diagnosis following two cycles of high-dose melphalan 200 mg/m² each supported by autologous stem cell retransfusion with interferon versus PEG-interferon. Patients with del(13) are screened for availability of a fully HLA-matched related or unrelated donor. If patient's informed consent is obtained additionally, he is scheduled to undergo an allogeneic SCT following the first cycle of high-dose melphalan. All other subjects are to proceed to a second course of high-dose melphalan similar to the standard-risk group. Initial cytoreduction is foreseen with four cycles of anthracycline-dexamethasone combination followed by combination therapy with ifosfamide/epirubicine/etoposide for stem-cell collection.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary diagnosis of multiple myeloma
  • Salmon-and-Durie stage II or III
  • Less than or equal to 60 years
  • Signed informed consent

Exclusion Criteria:

  • Relevant comorbidities
  • Unable to adhere to study protocol
  • Pregnancy
  • Not received subject's informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00546988

Contact: Hermann Einsele, M.D. +49/931/201-0 ext 70015
Contact: Stefan Knop, M.D. +49/931/201-0 ext 70368

Medizinische Univ.-Klinik Graz Recruiting
Graz, Austria, 8036
Contact: Werner Linkesch, MD    ++43(0)316/385-4086   
Principal Investigator: Werner Linkesch, MD         
Klin. Abt. für Onkologie, AKH Wien Recruiting
Vienna, Austria, 1090
Contact: Johannes Drach, MD   
Principal Investigator: Johannes Drach, MD         
Staedtisches Klinikum Recruiting
Augsburg, Germany, 86156
Dept. of Hematology/Oncology, Charité Berlin Recruiting
Berlin, Germany, 10098
Contact: Orhan Sezer, MD    030/450-513105   
Principal Investigator: Orhan Sezer, MD         
Charité University Medicine Recruiting
Berlin, Germany, 10117
Contact: Orhan Sezer, M.D.   
University Hospital Recruiting
Erlangen, Germany, 91054
Krankenhaus Nordwest Recruiting
Frankfurt, Germany, 60488
Freiburg University Hospital Recruiting
Freiburg, Germany, 79106
Contact: Monika Engelhardt, M.D.   
Georg August University Hospital Recruiting
Gottingen, Germany, 37075
Ernst-Moritz Arndt University Hospital Recruiting
Greifswald, Germany, 17478
Martin-Luther University Hospital Recruiting
Halle/Saale, Germany, 06120
Contact: Hans H Wolf, M.D.   
University Hospital Eppendorf Recruiting
Hamburg, Germany, 20246
Hannover Medical School Recruiting
Hannover, Germany
Contact: Dietrich Peest, M.D.    +49/511-532-0 ext -27765   
Saarland University Hospital Recruiting
Homburg/Saar, Germany, 66421
Contact: Michael Pfreundschuh, M.D.    +49/6841-162-0 ext 3003   
Schleswig-Holstein University Hospital Recruiting
Lubeck, Germany, 23538
Mainz University Hospital Recruiting
Mainz, Germany, 55131
Dept. of Internal Medicine A, University Muenster Recruiting
Muenster, Germany, 48129
Contact: Martin Kropff, MD   
Sub-Investigator: Martin Kropff, MD         
Dept. of Internal Medicine, Ludwig-Maximilian-University Munich Recruiting
Munich, Germany, 80336
Contact: Christian Straka, MD    089/5160-2278   
Principal Investigator: Christian Straka, MD         
Klinikum rechts der Isar Recruiting
Munich, Germany, 81675
Nuremberg Central Hospital Recruiting
Nuremberg, Germany
Contact: Hannes Wandt, M.D.    +49/911/398-0 ext 3090   
Oldenburg Hospital Recruiting
Oldenburg, Germany, 26133
Contact: Bernd , Metzner    +49/441/403-0 ext 2376   
University Hospital Recruiting
Regensburg, Germany, 93053
Katharinenhospital Recruiting
Stuttgart, Germany, 70173
Contact: Hans G Mergenthaler, M.D.    +49/711/253-0 ext 2501   
Diakonissenkrankenhaus Recruiting
Stuttgart, Germany, 70176
Tubingen University Hospital Recruiting
Tubingen, Germany, 72076
Contact: Katja Weisel, M.D.    +49/7071/29-0 ext -82711   
Dept. of Internal Medicine III, University of Ulm Recruiting
Ulm, Germany, 89081
Contact: Peter Liebisch, MD    0731/500-33809   
Principal Investigator: Peter Liebisch, MD         
Ulm University Hospital Recruiting
Ulm, Germany, 89081
Horst-Schmidt-Kliniken Recruiting
Wiesbaden, Germany, 65199
Contact: Norbert Frickhofen, M.D.    +49/611/43-0 ext 3009   
Dept. of Internal Medicine II, University of Wuerzburg Recruiting
Wuerzburg, Germany, 97070
Contact: Hermann Einsele, MD    +4993120170011   
Sub-Investigator: Volker Kunzmann, MD         
Sub-Investigator: Stefan Knop, MD         
Sponsors and Collaborators
University of Wuerzburg
Principal Investigator: Hermann Einsele, M.D. Wuerzburg University Hospital, Dept. of Hematology and Oncology
  More Information

Additional Information: Identifier: NCT00546988     History of Changes
Other Study ID Numbers: DSMM V
Study First Received: October 17, 2007
Last Updated: October 17, 2007

Keywords provided by University of Wuerzburg:
primary treatment
allogeneic stem-cell transplantation
high-dose therapy

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases processed this record on August 17, 2017